Ripretinib

Introduction Overview

Generic Name

ripretinib

Brand Name

Qinlock

Dosage Form

Oral tablet

Drug Class

Multikinase inhibitors

Pharmacokinetics

Absorption:
Ripretinib is administered orally as tablets. Following oral administration, ripretinib is absorbed through the gastrointestinal tract. It exhibits sufficient oral bioavailability allowing for once-daily dosing. Absorption is not significantly influenced by food intake, and tablets may be taken with or without food, facilitating patient adherence. The exact Tmax (time to peak plasma concentration) has been reported within 4 to 24 hours post-dose, indicating relatively rapid gastrointestinal absorption.

Distribution:
Ripretinib is extensively distributed throughout body tissues, consistent with its ability to inhibit kinases in tumor tissues. Plasma protein binding is high, exceeding 99%, primarily to albumin, indicating limited free drug in circulation but prolonged exposure. The volume of distribution suggests extensive extravascular tissue penetration, important for targeting gastrointestinal stromal tumors (GIST). Distribution to the central nervous system appears limited due to the blood-brain barrier, minimizing CNS-related side effects.

Metabolism:
Ripretinib is predominantly metabolized via cytochrome P450 3A4 (CYP3A4) isoenzyme. The metabolic pathway involves oxidative metabolism leading to the formation of active metabolites which contribute to its pharmacodynamic activity. Co-administration with CYP3A4 inhibitors or inducers can significantly alter plasma levels of ripretinib, impacting efficacy and safety. The presence of active metabolites also warrants consideration in drug interaction and dosing adjustments.

Elimination:
The elimination half-life of ripretinib and its active metabolites supports once-daily dosing and is approximately 15 to 20 hours. Excretion occurs mainly through feces, with minimal renal elimination. Hepatic clearance plays a significant role, and impaired liver function may necessitate careful monitoring or dosage adjustment. The enterohepatic recycling of ripretinib or its metabolites has not been clearly defined but may contribute to its pharmacokinetic profile. Overall, elimination mechanisms support its therapeutic use in chronic treatment of advanced GIST.

Dosage Forms

Available Dosage Forms:
- Oral tablet: 50 mg per tablet

Dosages for Adults and Adolescents:
- Recommended dose is 150 mg taken orally once daily
- Treatment continues until disease progression or unacceptable toxicity occurs

Specific Patient Populations:
- Indicated exclusively for adults with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with three or more kinase inhibitors, including imatinib
- No pediatric dosing established; safety and efficacy in patients below 18 years have not been established
- Adjustments in dosing may be necessary in cases of toxicity and in patients undergoing treatment with drugs affecting CYP3A4 metabolism

Clinical guidelines emphasize adherence to the prescribed dose without crushing, chewing, or breaking tablets. Tablets should be swallowed whole at consistent times daily, with or without food. Specific dose modifications for hepatic or renal impairment have not been defined in detail, warranting close clinical monitoring in these populations.

Mechanism Of Action

Ripretinib is a potent, broad-spectrum tyrosine kinase inhibitor designed to target KIT and PDGFRA kinases, which are commonly mutated and constitutively active in gastrointestinal stromal tumors (GIST). By binding to the switch control pocket of these kinases, ripretinib stabilizes them in an inactive conformation, effectively inhibiting downstream signaling pathways that promote tumor cell proliferation and survival.

At the molecular level, ripretinib acts as a switch-control inhibitor, meaning it binds to a regulatory region distinct from the ATP-binding site, which allows it to overcome resistance mutations that often limit the efficacy of earlier generation tyrosine kinase inhibitors. This unique binding provides a broader spectrum of activity against multiple resistant kinases and mutations within KIT and PDGFRA, including those that confer resistance to imatinib, sunitinib, and regorafenib.

Cellular pathways affected include interruption of the MAPK and PI3K/AKT pathways, both central to cell proliferation and survival signaling cascades. By inhibiting these, ripretinib induces apoptosis and halts cell cycle progression in cancer cells driven by activating mutations. Clinical studies demonstrate that ripretinib delays disease progression in patients with multiple prior TKI therapies.

Comparatively, ripretinib differs from earlier TKIs such as imatinib by its unique switch control mechanism, leading to enhanced coverage of both primary and secondary resistance mutations. This has been confirmed in phase III clinical trials showing improved progression-free survival in heavily pretreated GIST patients. Additional research is ongoing to further elucidate the full spectrum of ripretinib’s kinase inhibition and its impact on mutation-driven tumor heterogeneity.

Pharmacological Actions

Inhibition of KIT and PDGFRA receptor tyrosine kinases involved in tumor growth
Broad-spectrum multikinase inhibition effective against wild-type and mutant kinases
Switch-control inhibition stabilizing kinases in inactive conformations
Suppression of downstream proliferative and survival signaling pathways such as MAPK and PI3K/AKT
Induction of apoptosis in malignant gastrointestinal stromal tumor cells
Overcoming resistance to first- and second-line tyrosine kinase inhibitors
Reduction of tumor cell proliferation in advanced GIST cases
Oral bioavailability facilitating sustained systemic exposure
Modulation of kinase activity linked to decreased tumor progression
Potential interactions with CYP3A4 substrates due to metabolism
Minimal penetration into central nervous system reducing neurological toxicity risk
Prolongation of progression-free survival in heavily pretreated patients
Dose-dependent inhibition correlating with clinical response
Activity against secondary mutations associated with treatment resistance
Selective targeting contributing to manageable safety profile

Therapeutic Or Clinical Uses

Treatment of advanced gastrointestinal stromal tumor (GIST) in adults
Indicated for patients with GIST who have failed at least three prior kinase inhibitor therapies including imatinib
Management of unresectable or metastatic GIST
Therapy for tumors harboring KIT or PDGFRA mutations
Utilized to delay disease progression in advanced-stage GIST
Employed as a late-line treatment option after resistance to earlier TKIs
Part of targeted cancer therapy regimens for GIST
Potential investigational use in combination therapies involving kinase inhibitors
Provides treatment alternatives for patients with limited options due to resistance
Supports improvement in quality of life by tumor burden reduction
Prescribed under oncologist supervision for molecularly confirmed GIST
Maintaining long-term control of tumor growth in resistant disease
Used in clinical practice following FDA approval for specified indication
Applicable in settings requiring oral administration for convenience
Recommended with careful monitoring for treatment response and toxicity

Side Or Adverse Effects

Nausea and vomiting, often mild to moderate in severity
Abdominal or stomach pain associated with treatment
Loss of appetite leading to potential weight changes
Diarrhea or constipation as gastrointestinal disturbances
Fatigue and tiredness related to systemic therapy
Muscle pain and musculoskeletal discomfort
Hair thinning or alopecia including partial hair loss
Palmar-plantar erythrodysesthesia syndrome (hand-foot syndrome), manifesting as redness, swelling or pain on palms and soles
Hypertension requiring regular monitoring during treatment
Anemia presenting as pale skin, dizziness, or shortness of breath
Cardiac toxicity signs including shortness of breath, chest discomfort, or swelling
Skin changes including new warts, sores, or lesions suspicious for skin cancer
Headache and visual disturbances reported in some patients
Potential for hypersensitivity reactions including rash and hives
Elevations in liver enzymes reflecting hepatic irritation

Precautions

Use with caution in patients with uncontrolled or untreated hypertension
Monitor blood pressure regularly during treatment
Screen patients for history of palmar-plantar erythrodysesthesia syndrome prior to initiation
Evaluate cardiac function periodically due to risk of cardiac toxicity
Assess liver function tests as ripretinib is hepatically metabolized
Avoid exposure to excessive sunlight or tanning beds due to photosensitivity and risk of skin cancer
Advise patients on effective contraception as the drug may harm unborn babies
Do not breastfeed during treatment and for at least one week after last dose
Caution in patients with recent surgery or those planning elective surgery
Avoid abrupt discontinuation without medical consultation
Ensure thorough discussion regarding potential fertility effects in male patients
Monitor for signs of anemia and provide supportive care as needed
Be alert for gastrointestinal symptoms that may impact hydration and nutrition
Use caution in co-administration with CYP3A4 modulators affecting drug levels
Advise patients to report any new or changing skin lesions promptly

Warnings

May impair male fertility and affect the ability to father a child
Potential teratogenicity: ripretinib can harm an unborn baby; effective contraception required for both males and females
May increase the risk of skin cancer; regular dermatologic examination is recommended
Serious cardiovascular events including heart failure and hypertension reported
Risk of severe palmar-plantar erythrodysesthesia syndrome necessitates vigilance
Discontinue or modify dose if severe adverse reactions or intolerances occur
Avoid exposure to direct sunlight and UV radiation to reduce photosensitivity reactions
Potential for severe hypersensitivity or allergic reactions including anaphylaxis
Possibility of bleeding or hematologic toxicities requiring monitoring
Treatment may need to be interrupted during surgical procedures
Risk of hepatotoxicity manifested by elevated liver enzymes or clinical hepatitis
Pregnancy category risks necessitate negative pregnancy testing prior to therapy initiation
Do not breastfeed during treatment and for at least 1 week after last dose due to excretion in milk
Potential QT prolongation effects require monitoring in susceptible patients
Use caution in patients with co-morbidities affecting cardiac, hepatic, or renal function

Contraindication

Known hypersensitivity to ripretinib or any of its excipients
Presence of untreated or uncontrolled hypertension
Patients planning to become pregnant or who are pregnant
Breastfeeding women due to potential for drug excretion in breast milk
Severe hepatic impairment where metabolism and elimination may be compromised
Concurrent use with drugs contraindicated due to CYP3A4 metabolism interactions leading to toxicity
Patients who have not failed prior tyrosine kinase inhibitor therapies for GIST as efficacy is not established
Known or suspected allergy to multikinase inhibitors
Severe cardiac conditions where additional cardiac risk is unacceptable
Conditions predisposing to severe bleeding or hematologic complications without adequate control
Individuals unable to adhere to monitoring requirements for blood pressure and cardiac function
Concurrent use of ripretinib with live vaccines due to immunosuppressive potential
Use in pediatric patients due to lack of established safety and efficacy
Patients with active infections or immunocompromised status where treatment risk outweighs benefit

Drug Interactions

CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) may increase ripretinib plasma levels and toxicity
CYP3A4 inducers (e.g., rifampin, carbamazepine) may reduce ripretinib efficacy by lowering drug levels
Concurrent use with blood pressure medications may require dose adjustment due to potential additive hypotensive or hypertensive effects
Drugs that prolong QT interval may have additive cardiac risks when combined with ripretinib
Co-administration with other kinase inhibitors requires careful monitoring to avoid overlapping toxicities
Herbal supplements such as St. John’s wort which induce CYP3A4 may decrease ripretinib exposure
Anticoagulants may potentiate bleeding risk when used alongside ripretinib
Coadministration with strong CYP3A4 modulators requires close therapeutic drug monitoring
Medications metabolized by CYP3A4 may have altered plasma concentrations in presence of ripretinib
Combination with immunosuppressants may increase infection risk
Avoid grapefruit products which inhibit CYP3A4 and may increase drug levels
Interaction with vitamins or supplements affecting hepatic enzyme activity should be disclosed to the prescriber
Potential interaction with P-glycoprotein substrates impacting absorption or excretion
Careful assessment is needed when adding or discontinuing concomitant medications during ripretinib therapy
Interaction potential necessitates detailed medication reconciliation before initiating therapy

Preparations Of The Drug

Qinlock is prepared as oral tablets containing 50 mg of ripretinib each
Tablets are coated and intended for oral administration without crushing, chewing, or breaking
Packaged in moisture-resistant containers with desiccant packets to maintain drug stability
Storage recommended at room temperature away from heat and moisture to preserve potency
Supplied in bottles with child-resistant caps
Each bottle contains sufficient tablets for dosing as prescribed, generally 150 mg daily achieved by taking three 50 mg tablets
Comes with patient information leaflets detailing administration, storage, and precautions
Available only by prescription due to specialized indication and monitoring requirements
Manufactured under stringent quality control to ensure dose accuracy and tablet uniformity
Provision for dose titration or interruption by healthcare providers based on tolerability
No injectable, liquid, or alternative formulations currently available
Compatible with administration with or without food, improving patient compliance
Packaging includes instructions to keep tablets in original container until use
Disposal instructions emphasize proper handling of unused or expired tablets according to local regulations
Manufactured to meet FDA standards for safety and efficacy as a multikinase inhibitor